Intelligence · Clinical Development
Pipeline search results
Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Nivolumab
Takeda
Relapsed Multiple Myeloma
1 trial -
ONC201
Jazz Pharmaceuticals Ireland Limited
Multiple Myeloma
1 trial -
Opaganib
Apogee Therapeutics
Multiple Myeloma
1 trial -
PD-L1 peptide
IO Biotech
Smoldering Multiple Myeloma
1 trial -
PHE885
Novartis Pharmaceuticals
Multiple Myeloma
1 trial -
Panobinostat Capsules
pharmaand GmbH
Multiple Myeloma
1 trial -
Pomalidomide
Celgene Europe Limited
Multiple Myeloma
1 trial -
REGN5459
Regeneron UK Limited
Relapsed Multiple Myeloma
1 trial -
SDX-101 (R-Etodolac)
Teva Pharma GmbH
Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Multiple Myeloma in Relapse
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Relapse Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Smoldering Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Relapsed and Refractory Multiple Myeloma
1 trial -
Selinexor 20 MG Oral Tablet
Karyopharm Therapeutics Inc
Multiple Myeloma
1 trial -
Selinexor 60 MG
Karyopharm Therapeutics Inc
Multiple Myeloma
1 trial -
Sonrotoclax
BEONE MEDICINES AUS PTY LTD
Relapsed/Refractory Multiple Myeloma
1 trial -
TAK-981
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
1 trial -
TG-0054
Structure Therapeutics
Multiple Myeloma
1 trial -
TG-0054 (2.24 mg/kg)
Structure Therapeutics
Multiple Myeloma
1 trial -
TG-0054 combined with G-CSF
Structure Therapeutics
Multiple Myeloma
1 trial -
ZIO-101 (Darinaparsin)
Alaunos Therapeutics
Multiple Myeloma
1 trial -
anti-BCMA-CAR-T
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
2 trials -
anti-BCMA/CD3 bispecific antibody
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.